New developments in the treatment of cutaneous leishmaniasis

Leishmaniasis, including the cutaneous form, poses an important public health threat around the world, while no vaccine is currently available against any form of leishmaniasis. The drugs used in the first line treatment of cutaneous leishmaniasis (CL) are commonly pentavalent antimonials despite their toxicities, long-term treatment duration and increasing resistance rates. Other alternatives are amphotericin B, pentamidine, miltefosine and paromomycine. Movement of the population, especially in endemic regions, increases the spread of the parasite and affectes the distribution of causative species, which requires re-evaluation the treatment regimen. Extensive researches are carried out on the treatment of leishmaniasis. The immunotherapeutic and targeted therapeutic approaches, formulations of carrier-loaded active drugs, local thermotherapeutic applications, the combination of antileishmanial drugs/compounds, the use of new synthetic and natural products are promising therapeutic options in the future. Herein, the author reviews the potential treatment modalities of CL with a brief overview of current treatments in the light of ongoing studies around the world.

Therapeutic effects of blood purification in 160 cases with liver failure / 中国中西医结合急救杂志

Objective: To evaluate the clinical efficacy of various methods of blood purification in the treatment of patients with liver failure.Methods: Two hundred and seventy-three patients suffering from liver failure were randomly divided into two groups.On the base of medical routine treatment,160 patients were additionally treated with various methods of blood purification treatment group,including plasma exchange,plasma exchange associated with continuously venovenous hemofiltration,plasma exchange associated with hemodiafiltration,plasma exchange associated with plasma absorption,molecular absorbents recycling(system) and so on.While the other 113 patients received medical routine treatment only(control group).The efficacy of treatment and prognosis in the two groups were then observed and compared.Results: In the treatment group,the total bilirubin(TB),albumin(ALB),total bile acid(TBA),alanine aminotransferase(ALT),pre-albumin(PALB),cholinesterase(CHE) and prothrombin activity(PTA) after the treatment were better compared with those before the treatment(all P

The etiology of deep venous thrombosis in the lower extremities and its synthetic therapies / 介入放射学杂志

Deep venous thrombosis in the lower extremities is a very common disease clinically and can greatly affect people in their work and life without proper treatment promptly.The author reviewed the etiology,diagnosis,preventive measures and the synthetic therapies for dealing the deep venous thrombosis in the lower extremities,especially concerning the interventional radiology.

A clinical analysis of synthetic therapy effect and prognostic factors in 107 patients with breast cancer / 重庆医科大学学报

Objective:To investigate the synthetic therapy effect and prognosticfactorsin 107 patientswith breastcancer and explore the relationship between some clinical-pathological factors and patients' prognosis.Methods:Between Jan,2000 and Dec,2003,the clinical-pathological materials of 107 breast cancer cases who have received synthetic therapy,including radiotherapy,surgery,chemotherapy and endocrine therapy,were analyzed.The correlation of age,menopausal status,tumor size,axillary lymph nodal status,TNM stage,hormone receptor status and endocrinetherapy with prognosis of breast cancer was evaluated.Results:The overall survival and disease-free survival of the whole patients were 90.3 and 74.8 months,respectively.Analysis revealed that overall survival and disease-free survival of this group were significantly associated with tumor size,axillary lymph nodal status and TNMstage(P0.05).Conclusion:Our data demonstrate that tumor size,axillary lymph nodal status and TNM stage are significant independent indicators of prognosis in breast cancer respectively,and age,menopausal status,hormone receptor status and endocrine therapy are not significant factors of prognosis.